| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5912268 | JANSSEN PHARMS | Dosage form and method for treating incontinence |
May, 2015
(8 years ago) | |
| US5674895 | JANSSEN PHARMS | Dosage form comprising oxybutynin |
May, 2015
(8 years ago) | |
| US6262115 | JANSSEN PHARMS | Method for the management of incontinence |
May, 2015
(8 years ago) | |
| US5840754 | JANSSEN PHARMS | Dosage form comprising oxybutynin |
May, 2015
(8 years ago) | |
|
US5840754 (Pediatric) | JANSSEN PHARMS | Dosage form comprising oxybutynin |
Nov, 2015
(8 years ago) | |
|
US5674895 (Pediatric) | JANSSEN PHARMS | Dosage form comprising oxybutynin |
Nov, 2015
(8 years ago) | |
|
US6262115 (Pediatric) | JANSSEN PHARMS | Method for the management of incontinence |
Nov, 2015
(8 years ago) | |
|
US5912268 (Pediatric) | JANSSEN PHARMS | Dosage form and method for treating incontinence |
Nov, 2015
(8 years ago) | |
Ditropan Xl is owned by Janssen Pharms.
Ditropan Xl contains Oxybutynin Chloride.
Ditropan Xl has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Ditropan Xl are:
- US5912268
- US5674895
- US6262115
- US5840754
- US5840754*PED
- US5674895*PED
- US6262115*PED
- US5912268*PED
Ditropan Xl was authorised for market use on 16 December, 1998.
Ditropan Xl is available in tablet, extended release;oral dosage forms.
Ditropan Xl can be used as management of incontinence, mgt of hormone replacement therapy, treatment of involuntary incontinence, mgt overactive bladder and increasing compliance in such pt.
The generics of Ditropan Xl are possible to be released after 22 November, 2015.
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 16 December, 1998
Treatment: Management of incontinence, mgt of hormone replacement therapy, treatment of involuntary incontinence, mgt overactive bladder and increasing compliance in such pt
Dosage: TABLET, EXTENDED RELEASE;ORAL
DITROPAN XL family patents
